Background {#Sec1}
==========

Lung cancer is the primary cause of cancer-related death worldwide. It is well known that smoking is a major risk factor for lung cancer \[[@CR1]\]. Smoking causes emphysema and chronic obstructive pulmonary disease (COPD) \[[@CR2], [@CR3]\]. Several studies have found that emphysema and COPD are independent risk factors for lung cancer \[[@CR4]--[@CR6]\], especially squamous cell lung carcinoma (SCC) \[[@CR7], [@CR8]\].

The efficacy of immune checkpoint inhibitors has been established for SCC that express programmed death ligand 1 (PD-L1) \[[@CR9], [@CR10]\]. Although targeted therapy against adenocarcinoma with epidermal growth factor receptor (EGFR) gene mutation or anaplastic lymphoma kinase (ALK) and ROS1 proto-oncogene receptor tyrosine kinase (ROS1) rearrangements have shown dramatic effects \[[@CR11]--[@CR13]\], few targeted therapies against SCC have been identified. Previous reports have suggested that potential targets for therapy against SCC including fibroblast growth factor receptor 1 (FGFR1), phosphatidylinositol - 4,5 - bisphosphate 3 - kinase catalytic subunit alpha (PIK3CA), phosphatase and tensin homolog (PTEN), and p16 \[[@CR14]--[@CR17]\].

The genetic causes of emphysema and COPD are largely unknown \[[@CR18], [@CR19]\]. Furthermore, the developmental pathway between COPD and non-small cell lung cancer (NSCLC) remains elusive \[[@CR20]--[@CR22]\]. The purpose of this study was to evaluate PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression in SCC associated with emphysema and COPD.

Methods {#Sec2}
=======

Ethical considerations {#Sec3}
----------------------

This was a retrospective study approved by the institutional review board (Date of approval: Dec 27, 2012, approval number: 2693) of Tokyo Women's Medical University Hospital. Written informed consent was obtained from all patients before tumors were resected and additional consent was waived.

Patients population and samples {#Sec4}
-------------------------------

This study included 59 patients who underwent surgery for SCC between February 2008 and December 2012 at Tokyo Women's Medical University, Yachiyo Medical Center. All patients had computerized tomography (CT) and respiratory function tests to assess the suspected malignancy and determine eligibility for surgical intervention prior to surgery. Resected tumors were immediately fixed with 10% formalin, stained with hematoxylin and eosin (HE) and prepared for immunohistochemistry (IHC) staining.

Definition of emphysema {#Sec5}
-----------------------

The severity of emphysema on CT was visually assessed by two independent pulmonologists according to the Goddard scoring system \[[@CR23], [@CR24]\]. Low attenuation area (LAA) on six images of three lung slices (the right and left lungs were evaluated separately) were analyzed for each patient \[[@CR25]\]. Each image was scored as follows: score 0 (no LAA), score 1 (LAA of 1--25%), score 2 (LAA of 26--50%), score 3 (LAA of 51--75%), and score 4 (LAA of ≥76%) \[[@CR23]\]. Total severity score was categorized into one of three groups as follows: none-mild (0--7), moderate (8--15), and severe (≥ 16). Local severity score around the tumor was classified as no-emphysema (0) and presence of emphysema (1--4).

Definition of COPD {#Sec6}
------------------

Respiratory function tests were performed to assess the eligibility for surgery. Diagnosis of COPD was based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria after confirming the presence of persistent airflow limitation by a post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) \< 70% \[[@CR26]\]. The severity of air flow limitation was classified using the GOLD staging criteria with % predicted FEV1, as follows: GOLD 1 (≥ 80%), GOLD 2 (50--79%), GOLD 3 (30--49%), and GOLD 4 (\< 30%) \[[@CR26]\].

Molecular and IHC analysis {#Sec7}
--------------------------

PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression was evaluated by IHC staining of archived resected samples. IHC was performed with the following antibodies: PD-L1 (clone SP-142, diluted 1:100; Ventana Medical System, Arizona, USA), FGFR-1 (polyclonal, diluted 1:400; Abcam, Cambridge, UK), PIK3CA (Recombinant, diluted 1:400; Abcam), PTEN (clone 138G6, diluted 1:200; Cell Signaling, Massachusetts, USA), and p16 (Recombinant, diluted 1:2000; Abcam).

To improve the expression, the tissues were pre-treated with microwaves in ethylenediaminetetraacetic acid for PD-L1, or in retrieval solution (DAKO Target Retrieval Solution pH 9, Glostrup, Denmark) for FGFR1 in citrate buffer for PTEN and p16, before staining. Positive controls in IHC protocols were specimens from pulmonary SCC where the target molecules have been confirmed to be positive. To validate the specificity of the secondary antibody, negative reaction control sections obtained by omission of the primary antibody were used. IHC expression was evaluated by one experienced pathologist and pulmonologist in a blinded fashion. Each expression of tumor cells was classified by staining as follows: tumor cells (TC) 3 (≥ 50%), TC2 (5--49%), TC1 (1--4%), and TC0 (\< 1%) \[[@CR27]\]. Furthermore, tumor-infiltrating immune cells were also evaluated for PD-L1 as follows: immune cells (IC) 3 (≥ 50%), IC2 (5--49%), IC1 (1--4%), and IC0 (\< 1%). Immune cells were evaluated only for PD-L1, based on a previous study \[[@CR27]\]. If the score did not initially agree between evaluators, a discussion was initiated. Analysis of PD-L1 expression was as follows: TC0 vs. TC1, 2, 3, TC0, 1 vs. TC 2, 3, TC0, 1, 2 vs. TC3 and IC0 vs. IC1, 2, 3, IC0, 1 vs. IC 2, 3, IC0, 1, 2 vs. IC3. Analysis of FGFR1, PIK3CA, PTEN, and p16 expression was as follows: TC0 vs TC1, 2, 3.

Data analysis {#Sec8}
=============

Each expression of IHC was compared between none-mild (0--7) and mild-severe (8--24) emphysema groups of total Goddard scoring, no-emphysema (0) and presence of emphysema (1--4) tumor area groups, non-COPD and COPD groups, and GOLD 1 and GOLD 2, 3 groups. Data analysis was carried out using Statistical Analysis System (SAS institute, Cary, NC) and Graph Pad PRISM (GraphPad Software, La Jolla, CA). *P* values \< 0.05 were regarded as statistically significant. The *t*-test was used to compare between each expression and Goddard score. Chi-squared test was used to compare between each expression and severity of emphysema, presence of COPD/Gold staging. Groups were compared using 95% confidence intervals (CI).

Results {#Sec9}
=======

Baseline characteristics and molecular classification by staining {#Sec10}
-----------------------------------------------------------------

A total of 59 patients with surgically resected SCC were eligible for this study. Patient baseline characteristics included sex, median age, smoking history, histology, pathological stage, total severity of emphysema, local severity of emphysema, presence of COPD, and GOLD stage (Table [1](#Tab1){ref-type="table"}). There were no significant differences between total emphysema status, local emphysema status, COPD status and GOLD stage based on sex, smoking history and stage (Table [2](#Tab2){ref-type="table"}). Classifications of TC0--3, IC0--3 for PD-L1 (Fig. [1](#Fig1){ref-type="fig"}) and of TC0--3 for FGFR1, PIK3CA, PTEN, and p16 expression were recorded (Table [3](#Tab3){ref-type="table"}). Table 1Patient characteristicsPatient CharacteristicsNo (%)Patients59Median age (range)72.7 (56--85)Sex Male50 (84.7) Female9 (15.3)Smoking history Ever57 (96.6) Never2 (3.4) Median pack year (range)58.9 (0--184)Histology Squamous cell carcinoma59 (100)Pathological stage I38 (64.4) II16 (27.1) III4 (6.8) recurrence1 (1.7)Severity of emphysema mild40 (67.8) moderate14 (23.7) severe5 (8.5)Local severity of emphysema non23 (39.0) presence36 (61.0)Presence of COPD No COPD29 (49.2) COPD30 (50.8)Staging of GOLD GOLD137 (62.7) GOLD221 (35.6) GOLD31 (1.7)*COPD* chronic obstructive pulmonary disease, *GOLD* Global Initiative for Chronic Obstructive Lung Disease Table 2Comparison of patient characteristics based on total emphysema, local emphysema, COPD, and GOLD stageFactorsnone-mildmoderate-severe*P* valueNo Local emphysemaLocal emphysema*P* valueNo COPDCOPD*P* valueGOLD1GOLD2,3*P* valueSEX Male33170.7818320.5426240.5934160.14 Female72543636Smoking Never200.61200.2200.34200.54 Ever3819213627303522Stage I27110.6316220.8421170.6228100.17 II1065117979 III31221322recurrence01010101 Fig. 1Representative image of PD-L1 expression for each staining level (10X). A TC0 and IC0 (\< 1%), B TC1 and IC1 (1--4%), C TC2 and IC2 (5--49%), D TC3 and IC3 (50--100%). *PD-L1* programmed death ligand 1, *TC* tumor cells, *IC* immune cell Table 3Classification of each expressionClassify of expression (%)PD-L1FGFR1PIK3CAPTENp16TC07 (11.9)26 (44.1)55 (93.2)35 (59.3)22 (37.3)TC112 (20.3)15 (25.4)3 (5.1)8 (13.6)19 (32.2)TC217 (28.8)17 (28.8)1 (1.7)15 (25.4)16 (27.1)TC323 (39.0)1 (1.7)0 (0)1 (1.7)2 (3.4)IC01 (1.7)IC12 (3.4)IC225 (42.4)IC331 (52.5)*PD-L1* programmed death ligand 1, *FGFR1* fibroblast growth factor receptor 1, *PIK3CA* phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, *PTEN* phosphatase and tensin homolog, *TC* tumor cells, *IC* immune cell

Comparison between each classification of expression and severity of emphysema {#Sec11}
------------------------------------------------------------------------------

IHC expression of each molecular antibody was compared to total/local severity of emphysema (Table [4](#Tab4){ref-type="table"}). PD-L1 expression was significantly correlated with total severity of emphysema in TC0, 1, 2 vs. TC3 (*P* = 0.012). However, there was no other significant association between classification of expression and total/local severity of emphysema. Since there was significant association in total severity of emphysema, the results between TC0, 1, 2 (PD-L1 0--49) and TC3 (PD-L1 50--100) for total severity of emphysema were compared. There was significant difference between groups (95% CI: 0.061--5.852, *P* = 0.045) (Fig. [2](#Fig2){ref-type="fig"}). Table 4Comparison between each classification of expression and severity of emphysema, presence of COPD, GOLD stagingTotal severity of emphysemaLocal severity of emphysemaPresence of COPDStaging of GOLDClassify of expressionnone-mildmoderate-severe*P* valuenonepresent*P* valueNo COPDCOPD*P* valueGOLD1GOLD2,3*P* valuePD-L1 TC0610.28520.06340.72520.61 TC1,2,33418183426263220 TC0,11450.59100.367120.191180.6 TC2,32614142622182614 TC0,1,220160.01213230.5717190.7122140.75 TC320310131211158 IC0100.49100.2010.32100.44 IC1,2,33919223629293622 IC0,1200.32200.07020.16200.27 IC2,33819213629283522 IC0,1,22070.3414130.0616110.151890.56 IC3201292313191913FGFR1 TC01790.728180.2513130.9114120.21 TC1,2,32310151816172310PIK3CA TC036190.1522330.5528270.3233220.11 TC1,2,340131340PTEN TC023120.6817180.0716190.5220150.29 TC1,2,31776181311177p16 TC01390.2710120.431480.0912100.32 TC1,2,32710132415222512*COPD* Chronic obstructive pulmonary disease, *GOLD* Global Initiative for Chronic Obstructive Lung Disease, *PD-L1* Programmed death ligand 1, *TC* Tumor cells, *IC* Immune cells, *FGFR1* Fibroblast growth factor receptor 1, *PIK3CA* Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, *PTEN* Phosphatase and tensin homolog Fig. 2Comparison between TC0, 1, 2 (PD-L1 0--49) and TC3 (PD-L1 50--100) based on Goddard score PD-L1 expression was more than 50% when Goddard score was low (95% CI: 0.061--5.852, \**P* = 0.045). *PD-L1* programmed death ligand 1

Comparison between each classification of expression and presence of COPD/ GOLD stage {#Sec12}
-------------------------------------------------------------------------------------

The results of each classification of expression and presence of COPD/Gold stage was compared (Table [4](#Tab4){ref-type="table"}). There was no significant association between classification of expression and presence of COPD/GOLD stage.

Discussion {#Sec13}
==========

Few reports have investigated the associations between TC, PD-L1, emphysema, mutational analysis, and COPD in NSCLC \[[@CR28], [@CR29]\]. One study on lung adenocarcinoma found that patients with emphysema had more PD-L1 positive cells than patients without emphysema \[[@CR28]\]. Another study on NSCLC showed that PIK3CA expression was significantly associated with COPD \[[@CR29]\].

In this study, PD-L1 expression was significantly correlated with severity of total emphysema in TC0, 1, 2 vs. TC3 (*P* = 0.012). Furthermore, there was a significant difference inversely in total severity of emphysema between TC0, 1, 2 (PD-L1 0--49) and TC3 (PD-L1 50--100) (95% CI: 0.061--5.852, *P* = 0.045). There were no other significant associations between classification of expression and total/local severity of emphysema, and between classification of expression and presence of COPD/GOLD stage. These results differ from previous studies on the associations between PD-L1 expression and emphysema in patients with lung adenocarcinoma \[[@CR28]\], and between PIK3CA gene mutation and COPD in patients with NSCLC \[[@CR29]\]. One explanation for this discrepancy is that our study focused on SCC while other studies focused on lung adenocarcinoma or NSCLC. Another is that our study focused on protein expression while other study focused on the gene mutation. These differences may have influenced the results and may account for the differences in PD-L1 expression and PIK3CA.

This study identified for the first time a significant association between high expression of PD-L1 (≥ 50%) and none-mild emphysema in SCC. However, the mechanism behind this association remains unknown. Previous studies have shown an increased proportion of PD-1 positive CD8 T-cells in the lungs of patients with COPD lung such as lung emphysema. This appeared to contribute to dysfunctional of CD8 T-cells \[[@CR30], [@CR31]\]. Our findings suggest that tumor need not escape from CD8 T-cell attack, particularly given the low expression of PD-L1 when emphysema is moderate-severe. On the contrary, if a tumor escapes CD8 T-cell attack, it might be attributed to high expression of PD-L1 in none-mild emphysema.

This study found that none-mild emphysema was an independent predictive factor of high PD-L1 expression (≥ 50%). This result suggests the utility of non-invasive ways of predicting high expression of PD-L1 (≥ 50%), such as CT imaging. CT imaging may also be an effective way of deciding to use immune checkpoint inhibitors \[[@CR9], [@CR10]\] in patients with SCC before determining PD-L1 expression with IHC. This might prevent significant life threatening events associated with surgery and bronchoscopy, such as decreasing respiratory function, embolism, bleeding, and pneumothorax. In addition, this might lead to insights regarding the mechanistic correlation between PD-L1 expression and emphysema.

This study had several limitations. First, this was a retrospective study performed at a single institution, which may have influenced the results. A prospective multicenter randomized control trial is needed to confirm our results. Second, although this study shows an association between each expression and Goddard, COPD, and GOLD stage, the associations between those and overall survival rates remain unknown. An evaluation of overall survival is needed. Third, although LAA was evaluated with Goddard criteria, it is unclear if the automated evaluation for LAA \[[@CR32]\] would provide the same results. Additional studies are needed to determine what methods are most appropriate for evaluating LAA.

Conclusion {#Sec14}
==========

In conclusion, there was a significant association between TC0, 1, 2 vs. TC3 groups and none-mild vs. moderate-severe emphysema groups in patients who underwent surgical resection of lung SCC. PD-L1 expression was significant higher in none-mild emphysema than in moderate-severe emphysema. There was no significant association between any other classification of expression for PD-L1, FGFR1, PIK3CA, PTEN, p16 and total/local severity of emphysema, between classification of expression for PD-L1, FGFR1, PIK3CA, PTEN, p16 and presence of COPD/GOLD staging. Further studies are needed to evaluate overall survival between classification of each expression and total/local severity of emphysema, presence of COPD/GOLD stage.
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:   Chronic obstructive pulmonary disease

GOLD
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SCC
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